Chitosan/Hyaluronic Acid Nanoparticles: Rational Design Revisited for RNA Delivery
- 19 June 2017
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 14 (7), 2422-2436
- https://doi.org/10.1021/acs.molpharmaceut.7b00320
Abstract
Chitosan/hyaluronic acid (HA) nanoparticles can be used to deliver an RNA/DNA cargo to cells overexpressing HA receptors such as CD44. For these systems, unequivocal links have not been established yet between chitosan macromolecular (molecular weight; degree of deacetylation, i.e., charge density) and nanoparticle variables (complexation strength, i.e., stability; nucleic acid protection; internalization rate) on one hand, and transfection efficiency on the other hand. Here, we have focused on the role of avidity on transfection efficiency in the CD44-expressing HCT-116 as a cellular model; we have employed two differently sized payloads (a large luciferase-encoding mRNA and a much smaller anti-Luc siRNA), and a small library of chitosans (variable molecular weight and degree of deactylation). The RNA avidity for chitosan showed—as expected—an inverse relationship: higher avidity–higher polyplex stability–lower transfection efficiency. The avidity of chitosan for RNA appears to lead to opposite effects: higher avidity–higher polyplex stability but also higher transfection efficiency. Surprisingly, the best transfecting particles were those with the lowest propensity for RNA release, although this might be a misleading relationship: for example, the same macromolecular parameters that increase avidity can also boost chitosan’s endosomolytic activity, with a strong enhancement in transfection. The performance of these nonviral vectors appears therefore difficult to predict simply on the basis of carrier- or payload-related variables, and a more holistic consideration of the journey of the nanoparticle, from cell uptake to cytosolic bioavailability of payload, is needed. It is also noteworthy that the nanoparticles used in this study showed optimal performance under slightly acidic conditions (pH 6.4), which is promising for applications in a tumoral extracellular environment. It is also worth pointing out that under these conditions we have for the first time successfully delivered mRNA with chitosan/HA nanoparticles.Keywords
Funding Information
- AstraZeneca
- Engineering and Physical Sciences Research Council (EP/G03737X/1)
- FP7 Health (601738)
- Innovate UK (101710)
This publication has 64 references indexed in Scilit:
- Mannosylation Allows for Synergic (CD44/C‐Type Lectin) Uptake of Hyaluronic Acid Nanoparticles in Dendritic Cells, but Only upon Correct Ligand PresentationAdvanced Healthcare Materials, 2016
- Identification of large channels in cationic PEGylated cubosome nanoparticles by synchrotron radiation SAXS and Cryo-TEM imagingSoft Matter, 2015
- Exploiting Endocytosis for NanomedicinesCold Spring Harbor Perspectives in Biology, 2013
- Chitosans for delivery of nucleic acidsAdvanced Drug Delivery Reviews, 2013
- The CD44/integrins interplay and the significance of receptor binding and re-presentation in the uptake of RGD-functionalized hyaluronic acidBiomaterials, 2012
- Chitosan-based formulations for delivery of DNA and siRNAAdvanced Drug Delivery Reviews, 2009
- Nanocarriers’ entry into the cell: relevance to drug deliveryCellular and Molecular Life Sciences, 2009
- Molecular design of functional polymers for gene therapyProgress in Polymer Science, 2007
- CD44 in CancerCritical Reviews in Clinical Laboratory Sciences, 2002
- CD44 cell adhesion moleculesMolecular Pathology, 1999